Loading…
MacroGenics, Inc. is projected to rise to $6.80 by 2027, a +55% move from its current price of $4.38. MGNX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.19 | $4.38 | $4.59 | +0.11% |
| May 30 | $4.11 | $4.39 | $4.68 | +0.23% |
| May 31 | $4.06 | $4.39 | $4.76 | +0.34% |
| Jun 1 | $4.01 | $4.40 | $4.82 | +0.45% |
| Jun 2 | $3.98 | $4.40 | $4.88 | +0.56% |
| Jun 3 | $3.94 | $4.41 | $4.93 | +0.68% |
| Jun 4 | $3.91 | $4.41 | $4.98 | +0.79% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.91 | $4.41 | $4.98 | +0.79% |
| Week 2 | $3.75 | $4.45 | $5.28 | +1.59% |
| Week 3 | $3.64 | $4.48 | $5.53 | +2.39% |
| Week 4 | $3.55 | $4.52 | $5.76 | +3.20% |
| Week 5 | $3.47 | $4.56 | $5.98 | +4.02% |
| Week 6 | $3.41 | $4.59 | $6.18 | +4.84% |
| Week 7 | $3.36 | $4.63 | $6.38 | +5.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Its product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc. (MGNX) is trading at $4.53 per share. It has a market capitalization of $287.94M and holds a rank of 3568.
The near-term forecast shows a 2026 average price of $4.53 with a min of $1.61 and a max of $7.61, and a neutral sentiment.
Longer-term forecasts show substantial upside, with a 2030 average price of $9.24 and ROI of 103.9%, a 2040 average of $31.09 and ROI of 586.2%, and a 2050 average of $69.26 and ROI of 1429.
A major floor 61.2% below — a decisive break under it would weaken the trend.
The nearest floor, 32.9% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 26.5% above — clearing it would confirm fresh momentum.
Key MGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.42 | Sell | $4.38 | Sell |
| MA 10 | $4.28 | Buy | $4.20 | Buy |
| MA 20 | $3.69 | Buy | $3.90 | Buy |
| MA 50 | $3.39 | Buy | $3.40 | Buy |
| MA 100 | $2.67 | Buy | $2.90 | Buy |
| MA 200 | $2.14 | Buy | $2.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.28 | Neutral |
| Stoch RSI (14) | 68.61 | Neutral |
| CCI (20) | 74.79 | Neutral |
| Williams %R (14) | -9.43 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 46.00 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 90.57 | Sell |
| TRIX (15) | 1.15 | Buy |
| Awesome (5,34) | 0.86 | Buy |
| Ultimate (7,14,28) | 63.13 | Neutral |
| Momentum (10) | 0.86 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 4.47 | Sell |
| ADX (14) | 29.43 | Buy |
| ATR (14) | 0.15 | Info |
The sentiment is BULLISH. The RSI(14) is 70, with the 50-day simple moving average at $3.33 and the 200-day simple moving average at $2.11. Support is listed at $2.94 and resistance at $4.53. The 30-day price range is $3.29 to $6.24.
These near-term metrics suggest potential for upside within the 30-day window, with price action bounded by the stated support and resistance levels and a momentum backdrop indicated by a high RSI.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $4.38 | $7.25 | 0% | Neutral | |
| $5.04 | $6.80 | $9.90 | +55% | Bullish | |
| $5.44 | $7.72 | $11.86 | +76% | Bullish | |
| $5.19 | $7.67 | $12.29 | +75% | Bullish | |
| $6.00 | $9.22 | $15.31 | +111% | Bullish | |
| $6.60 | $10.51 | $18.00 | +140% | Bullish | |
| $8.52 | $14.02 | $24.68 | +220% | Bullish | |
| $10.85 | $18.45 | $33.28 | +321% | Bullish | |
| $9.82 | $17.22 | $31.77 | +293% | Bullish | |
| $9.37 | $16.93 | $31.89 | +287% | Bullish | |
| $15.27 | $31.84 | $65.34 | +627% | Bullish | |
| $31.37 | $69.70 | $160.31 | +14.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.61 | $4.38 | $5.22 | +0.00% |
| June 2026 | $3.98 | $4.74 | $5.83 | +8.17% |
| July 2026 | $4.01 | $4.85 | $6.11 | +2.44% |
| August 2026 | $3.97 | $4.85 | $6.21 | -0.04% |
| September 2026 | $4.19 | $5.17 | $6.70 | +6.55% |
| October 2026 | $4.40 | $5.48 | $7.20 | +6.09% |
| November 2026 | $4.31 | $5.41 | $7.17 | -1.44% |
| December 2026 | $4.28 | $5.41 | $7.25 | +0.04% |
Click any year to see its month-by-month MGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MGNX could reach as high as $7.25, with a base case around $4.38 and support toward $1.61 — roughly 0% from $4.38. A consolidation phase looks the most probable path here.
Expect MGNX to range from $5.04 to $9.90 through 2027. The $6.80 average target implies a +55% move from current prices. That is up +55% on the projected 2026 average. Momentum favours further upside here.
The MGNX price prediction for 2028 points to an average of $7.72 (low $5.44, high $11.86) — a potential gain of +76% on today's $4.38. Buyers look set to stay in control over this stretch.
In 2029, MGNX is projected to trade between $5.19 and $12.29, averaging $7.67 — a potential gain of +75% from today's $4.38. That is -1% versus the projected 2028 average. Momentum favours further upside here.
MacroGenics, Inc.'s 2030 outlook centres on $9.22, within a $6.00 to $15.31 range. That is up +20% on the projected 2029 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MGNX could reach as high as $18.00, with a base case around $10.51 and support toward $6.60 — roughly +140% from $4.38. Momentum favours further upside here.
Expect MGNX to range from $8.52 to $24.68 through 2032. The $14.02 average target implies a +220% move from current prices. That is up +33% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The MGNX price prediction for 2033 points to an average of $18.45 (low $10.85, high $33.28) — a potential gain of +321% on today's $4.38. Momentum favours further upside here.
In 2034, MGNX is projected to trade between $9.82 and $31.77, averaging $17.22 — a potential gain of +293% from today's $4.38. That is -7% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
MacroGenics, Inc.'s 2035 outlook centres on $16.93, within a $9.37 to $31.89 range. That is -2% versus the projected 2034 average. That marks a +287% change versus current levels. Momentum favours further upside here.
By 2040, MGNX could reach as high as $65.34, with a base case around $31.84 and support toward $15.27 — roughly +627% from $4.38. Buyers look set to stay in control over this stretch.
Expect MGNX to range from $31.37 to $160.31 through 2050. The $69.70 average target implies a +14.9x move from current prices. That is up +119% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MGNX today (≈ 228.310502 MGNX) could be worth
$15,913.32
+$14,913.32 (+1491%) by 2050 · US Dollar
Based on the average projected MGNX price of $69.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGNXwould be worth at today's price.
$1,000 invested in MGNX on May 27, 2025 (≈ 673.400667 MGNX) would be worth
$2,949.49
+$1,949.49 (+194.9%) today · 2.95× · US Dollar
Based on a MGNX entry price of $1.49 vs. today's $4.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.46 | $982.06 | -1.8% |
| 1 month ago | $3.05 | $1,436.07 | +43.6% |
| 3 months ago | $1.98 | $2,212.12 | +121.2% |
| 6 months ago | $1.53 | $2,862.75 | +186.3% |
| 1 year ago | $1.49 | $2,949.49 | +194.9% |
| All time (5.0y) ago | $32.34 | $135.44 | -86.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGNX forecast.
Our base-case forecast reaches $8.80 around 2030.
Implied market cap at $8.80: $559.36M
The multi-year forecast shows a clear upside path, with notable milestones in the 2030, 2040 and 2050 horizons. In 2030, the average price is projected at $9.24 with a return of 103.9% and a bullish sentiment. The forecast also shows a 2040 average of $31.09 with a 586.2% ROI and a bullish sentiment, followed by a 2050 average of $69.26 with a 1429% ROI and bullish sentiment.
Looking at the intermediate years, 2027 shows an average of $6.99 (ROI 54.3%), 2028 $7.82 (ROI 72.6%), and 2029 $7.74 (ROI 70.9%), all with bullish sentiment. These figures illustrate the potential upside across the forecast horizon, though they remain estimates and are not guaranteed.
Overall, the long-range outlook points to substantial upside from current levels, with the 2030, 2040, and 2050 targets anchoring an aggressively higher price trajectory. Investors should weigh these estimates against inherent uncertainties and market conditions when evaluating risk and potential reward.
Tap a question to reveal the answer.
2030 avg $9.24, min $5.89, max $15.62; ROI 103.9%; sentiment BULLISH.
The forecast shows bullish sentiment across multiple years with substantial upside, including 2030 avg $9.24, 2040 avg $31.09, and 2050 avg $69.26; these are estimates, not guarantees.
Yes. The 2040 max is $65.47 and the 2050 max is $159.30, so hitting $60 by 2040 is within the forecast range.
Current price is $4.53 and market cap is $287.94M.
RSI(14) is 70, the 30-day range is $3.29 to $6.24, SMA50 is $3.33, SMA200 is $2.11, with support at $2.94 and resistance at $4.53.
MacroGenics, Inc. Community Discussion
0Share your MacroGenics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.